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Objectives: To describe the role of bacteria (including bacterial resistance), viruses 
(including those recently described), and mixed bacterial-viral infections in adults presenting 
to primary care with lower respiratory tract infection (LRTI).  
Methods: We enrolled 3104 adults with LRTI, 141 (4.5%) of whom had community-acquired 5 
pneumonia (CAP), and 2985 matched controls in a prospective study in 16 primary care 
networks in Europe, and followed patients up at 28-35 days. We detected S. pneumoniae and 
H. influenzae and assessed susceptibility, atypical bacteria and viruses.  
Results: A potential pathogen was detected in 1844 (59%) (in 350 (11%) bacterial pathogens 
only, in 1190 (38%) viral pathogens only, and in 304 (10%) both bacterial and viral 10 
pathogens). The most common bacterial pathogens isolated were S. pneumoniae (5.5% 
overall, 9.2% in CAP patients) and H. influenzae (5.4% overall, 14.2% in CAP patients). <1% 
of S. pneumoniae were highly resistant to penicillin and 12.6% of H. influenzae were beta-
lactamase positive. The most common viral pathogens detected were human rhinovirus 
(HRV; 20.1%), influenza viruses (FLU; 9.9%), and human coronavirus (HCoV; 7.4%). FLU, 15 
human parainfluenzaviruses and human respiratory syncytial virus as well as HRV, HCoV, 
human metapneumovirus were detected significantly more frequently in LRTI patients than in 
controls.  
Conclusions: A bacterial pathogen is identified in approximately one in five adult patients 
with LRTI in primary care, and a viral pathogen in just under half, with mixed infections in 20 
one in ten. Penicillin resistant pneumococci and beta-lactamase producing H. influenzae are 
uncommon. These new findings support a restrictive approach to antibiotic prescribing for 


















Community-acquired lower respiratory tract infection (LRTI) is one of the commonest 
reasons for consulting in primary care and accounts for considerable antibiotic use and health 
care costs. It is neither feasible nor cost-efficient to identify microbial aetiology in most 
patients who present with LRTI in primary care because of sampling challenges, limited 5 
access diagnostics, and the limited clinical utility of receiving a result after empirical 
treatment decision has been made (1). Consequently, little is known about the aetiology of 
LRTI in everyday primary care. In addition, detecting pathogens in both symptomatic patients 
and contemporaneous controls to distinguish between asymptomatic carriage and the presence 
of agents causing symptoms has rarely been done. Neverth less, despite limited knowledge of 10 
the proportion of patients that have an identifiable acterial aetiology and the sensitivities of 
these pathogens, and evidence of limited or no clinical benefit from antibiotic treatment, more 
than half of patients presenting to primary care with LRTI/acute cough in Europe are 
prescribed antibiotics (2-4). This contributes to the selection of antimicrobial resistant bacteria 
(5). Improved knowledge of likely pathogens (at the point of care) and the likely 15 
susceptibility of bacterial pathogens, could help guide antibiotic prescribing decisions and 
thus help contain unnecessary antibiotic use and antimicrobial resistance. Furthermore, such 
information could support public health policy on prevention of respiratory illness including 
vaccination. 
 20 
Therefore, our primary objective was to describe the viral and bacterial aetiology in adult 
patients presenting to primary care with lrti and i those with community-acquired pneumonia 
(cap). our secondary objectives were to describe the presence of resistance in bacterial 
















MATERIALS AND METHODS  
Study design and patients  
The study was part of the European Union FP6 funded N twork of Excellence GRACE 
(Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe 
Network of Excellence; www.grace-lrti.org). We recruited patients between October 2007 and 5 
April 2010 in 16 primary care networks (PCNs) that d a track record of conducting research 
based in 11 European countries: Antwerp and Ghent (Belgium); Barcelona and Mataro (Spain); 
Bialystok, Lodz and Szczecin (Poland); Bratislava (Slovakia); Cardiff and Southampton (UK); 
Jesenice (Slovenia); Jönköping (Sweden); Milan (Italy); Nice (France); Rotenburg (Germany), 
and Utrecht (The Netherlands).  10 
Inclusion criteria for patients were: age ≥ 18 years, with an acute or worsened cough (≤28 days 
duration) as the main symptom, or any clinical presentation considered to be caused by LRTI 
by the general practitioner (GP) and consulting for the first time for this illness episode. 
Patients with presumed cough of non-infective origin, antibiotic consumption in the previous 
month, and any serious condition associated with an immunocompromised condition were 15 
excluded. For each patient, we planned to include a control patient matched for age, maximum 
5 years of difference, and gender, consulting at the GP office for any other reason than acute 
respiratory illness within the same two-week period. The study was approved by the local 
ethics committees in all participating centres and by the competent authority in each country. 
Written informed consent was obtained from each patient and control prior to inclusion.  20 
 
Sampling and Measurements  
Symptomatic patients were assessed at first presentatio  (day 1) and between days 28-35. 















pneumonia (CAP) was considered present if the local radiologist reported lobar or 
bronchopneumonia; other diagnoses were categorised as ‘pneumonia absent’ (6). 
All recruiting GPs received standardised sampling material and a protocol with detailed 
instructions on the sampling of the patients. Within 24 h of first presentation and inclusion, 
serum and EDTA blood, sputum, if available, and twonasopharyngeal flocked swabs (NPS; 5 
COPAN) were taken. At day 28-35, serum sampling and the two NPS were repeated. Controls 
were sampled for EDTA blood and two NPS at baseline. Sputum was not obtained from 
controls and controls were not followed up. Serum, EDTA and NPS were stored frozen in the 
local laboratories until regular shipment to the central laboratory (University Hospital 
Antwerp), where specimens were stored at -80°C until a alysis.  10 
 
Bacterial cultures for S. pneumoniae and H. influenzae 
  
Sputum samples were examined in the local laboratories using direct microscopy to assess the 
quality (ratio of white blood cells/epithelial cells ≥1 as criterion for good quality), then Gram 15 
stained, cultured, and subsequently frozen at -80°C. S. pneumoniae and H. influenzae were 
identified using conventional biochemical tests and isolates were frozen in microbanks until 
shipped in batches to the central laboratory, where NPS were cultured for S. pneumoniae 
and/or H. influenzae. Their susceptibility was tested at the Karolinska Institute and the Oxford 
University, respectively, after frozen transport. Minimum inhibitory concentrations (MICs) of 20 
S. pneumoniae to penicillin G, erythromycin, clindamycin, tetracycline, and levofloxacin were 
determined. Isolates were classified as sensitive, indeterminate or resistant according to the 
EUCAST breakpoints for these species (www.eucast.org/antimicrobial-susceptibility-
















PCRs for Mycoplasma pneumoniae, Chlamydia pneumoniae, Bordetella pertussis, Legionella 
pneumophila and respiratory viruses 
 
Nucleic acid from NPS was extracted with the NucliSens EasyMag (bioMérieux) in Antwerp 
after which aliquots were shipped and analysed in three collaborating laboratories  for 5 
subsequent analysis with their in-house amplification and detection methods evaluated 
previously (7).  
 
Serology for M. pneumoniae, C. pneumoniae and B. pertussis 
 10 
For the detection of M. pneumoniae-specific and C. pneumoniae specific IgG or IgM 
antibodies, M. pneumoniae or C. pneumoniae–IgG and IgM-ELISA kits (Medac GmbH) were 
used according to the instructions of the manufacturer. IgG antibodies to B. pertussis toxin 
(PT; Virion/Serion) were analysed in a convalescent s rum sample. 
 15 
Diagnostic criteria 
The isolation of S. pneumoniae and H. influenzae, and the identification of L. pneumophila or 
respiratory viruses by use of PCR in respiratory samples were considered to support an 
aetiological diagnosis. Infection with M. pneumoniae or C. pneumoniae was defined as: 
positive PCR in respiratory samples, the presence of IgM antibodies in the acute phase serum 20 
and/or convalescent phase sample, IgG seroconversion or a significant increase in IgG 
between acute and convalescent samples.  
A patient was considered positive for an acute B. pertussis infection (infection in the last 6 
months) if positive by PCR in a respiratory sample and/or the presence of an antibody titre to 
PT of ≥125 IU/ml in convalescent serum (day 28-35), demonstrated previously as a cut-off 25 

















Generalized Estimating Equations were used to assess differences in the proportion of 
potential pathogens between LRTI patients’ day 1 and day 28-35 samples, and between day 1 
samples of LRTI patients and controls. The case-control design was applied to assess 
causality between viral pathogens and LRTI (CAP). Chi-square tests were used to assess 5 
differences in the proportion of specific viruses or bacteria between LRTI patients with and 
those without CAP. Student t-test was used to assess differences in age between LRTI 
patients with and those without specific viral or bacterial aetiology (IBM® SPSS® Statistics, 

















Patient characteristics and response 
A total of 3104 adult LRTI patients were included by 294 GPs from October 2007 to April 
2010, 1860 (60.0%) were female (Table 1). The mean age was 49.8 years (range 18 - 92 
years) and 141 were diagnosed with CAP (4.5%); among elderly patients (>65 years n=628, 5 
20.2%) 40 patients had a CAP (6.4%). We recruited a tot l of 2985 controls without 
symptoms of LRTI.  
 
Day 1 NPS and blood samples were available from 3085 (99.4%) and 3054 (98.4%) LRTI 
patients, sputum samples in 2121 (68.3%). On day 28-35, 2673 patients (86.1%) were seen: in 10 
2552 (95.5%) and 2575 (96.3%) of these, blood samples and NPSs, respectively, could be 
collected. Only controls who matched with patients according to all criteria (n= 2063) were 
further included to estimate causality. 
 
Aetiology in LRTI and CAP in primary care  15 
The proportion of patients with LRTI and CAP with an identified bacterial, viral, and mixed 
aetiology is presented in figure 1. 
 
Bacterial aetiology and resistance in S. pneumoniae and H. influenzae.  
A potential bacterial pathogen was found in 655 (21.1%) LRTI patients on day 1, significantly 20 
more often in patients with CAP compared to those without (Figure 1 and Table 2). S. 
pneumoniae and H. influenzae were significantly more prevalent in patients presenting with 
CAP. 9.2% of all 3104 patients and 10.6% of CAP patients were vaccinated against S. 
















24/172 (14.0%) had a reduced susceptibility to penicilli  G (1 isolate highly resistant, 23 
(13.4%) intermediate resistance). Thirty-six (20.9%) isolates were less susceptible to 
erythromycin/clindamycin, 78 (45.3%) had a reduced susceptibility to tetracycline, and 3 
(1,7%) were resistant to levofloxacin. 21/167 (12.6%) H. influenzae isolates produced beta-
lactamases. 5 
 
Viral aetiology  
Any viral aetiology was identified in 1494 (48.1%) of LRTI patients, significantly less often 
in those with CAP compared to those without CAP (Figure 1 and Tables 2-3). The 
commonest viruses in our cohort of patients were HRV, FLU and HCoV. A respiratory virus 10 
was detected on day 28-35 in 336 patients (12.6%), as well as in 205 (9.9%) of matched 
controls. All respiratory viruses, except for HAdV, HBoV and WUPyV and KIPyV, were 
significantly more frequently detected in day 1 NPS of LRTI patients than in their day 28-35 
NPS or in the NPS of their matched controls (Table 3). Apart from HAdV, virus prevalence 
did not differ significantly between patients with CAP or with LRTI. 15 
23.6% of all LRTI patients and 29.1% of CAP patients were vaccinated against influenza. 
Prevalence of influenza in these groups was 5.3% and 4.9%, respectively. 
 
Detection of atypical bacterial agents or viruses at follow-up within the same patient  
Casewise analysis of atypical bacterial agents or viruses detected during illness compared to 20 
subsequent detection at follow-up is presented in Table 4. None of the patients who were 
initially PCR positive for M. pneumoniae, B. pertussis, FLU or HPIV 1-4 remained positive 
for these aetiologies at follow-up. Very few patiens positive for HRV, HCoV, RSV, hMPV, 

















Among all 3104 LRTI patients, a mixed bacterial, mixed viral or mixed bacterial-viral 
infection was detected in 51 (1.6%), 118 (3.8%) and304 (9.8%) patients, respectively. The 

















This is the only prospective, large international, case-control study using standardized 
sampling and comprehensive microbiological work up to provide accurate estimates of the 
prevalence of both bacterial and viral aetiology in patients consulting in primary care with 
LRTI. The overall microbiological yield was high, mainly due to the high prevalence of 5 
viruses. A potential bacterial pathogen was isolated in only one in five patients, and that 
antibiotic resistant pathogens were rare.  
 
Comparison with literature  
Previous studies have mainly studied more severely ill patients hospitalised with CAP rather 10 
than LRTI in primary care (1, 10-12), and few of those studies used comprehensive diagnostic 
methods, including PCR, to detect respiratory viruses (10, 12, 13). We identified a potential 
pathogen in about 60% of CAP patients. However, comparisons are difficult in that our study 
is unique in terms of study design, the broad inclusion criteria, the high numbers of patients 
sampled at baseline and follow up, the inclusion of matched controls, and comprehensive 15 
conventional and molecular microbiological diagnostics used.   
 
Bacterial aetiology and resistance in CAP 
The prevalence of S. pneumoniae and H. influenzae in our CAP subgroup were significantly 
higher than in the non-CAP patients, but lower in comparison to most previous studies. We do 20 
not consider that the implementation of pneumococcal vaccine influenced our findings 
because of the small number of CAP patients who had been vaccinated. However, only 5% of 
patients in the most comprehensive aetiological study of adult patients hospitalized with CAP 
in the US had pneumococcal pneumonia (14).  High level penicillin resistance in 
pneumococci remains very low in all European countries in this setting, which supports the 25 















agent for LRTI (1). M. pneumoniae infections occur in epidemics every 4-5 years: we 
included patients in our study between two epidemic waves, possibly explaining the low M. 
pneumoniae prevalence observed (15, 16).  This is also the first large European prospective 
study on the prevalence of pertussis in adults consulti g primary care physicians for acute 
cough (17). 5 
 
Importance of respiratory viruses, including newly detected viruses 
We detected at least one respiratory viral pathogen in almost 50% of patients. NPS sampling 
may have yielded significantly more infected respirato y epithelial cells (18), with sensitive 
PCR based diagnostic techniques augmenting specifically for viruses.   10 
 
FLU, HPIV 1-4 and RSV viruses are recognised causes of CAP in hospitalised patients and in 
the elderly(13), 22, 24. Influenza vaccination resulted in lower prevalence of FLU in the elderly 
(data not shown). HRV, HCoV, and HMPV are rarely detected in CAP and other LRTI in 
outpatients.  15 
HRV has been associated with outbreaks of severe respiratory disease, including CAP, in 
older people (19-21) and has been isolated in hospitalized patients with CAP (10), but a 
prevalence of 14.2% in CAP in outpatients is high and  novel finding. HCoV have recently 
been identified in small numbers of adults with sever  pneumonia (10, 21), but is not 
routinely tested for in adult outpatients with CAP or LRTI. We may have underestimated the 20 
prevalence of HCoV as HKU-1 testing was not performed and HKU-1 is generally as 
prevalent as NL63 and OC43 (22). Infections due to HMPV are mainly described in long term 
care facilities (10). We found HMPV more prevalent in outpatients with CAP compared to 
those with other LRTIs, with even greater prevalence in CAP patients than RSV, and similar 















numbers are small, HAdV was significantly more preval nt in CAP compared to other LRTI, 
a unique finding in immunocompetent outpatients. The high rates of viral detection in 
outpatients with LRTI and CAP suggests that comprehensive microbiological assessment is 
important to guide management and may explain the limited average benefit from antibiotic 
treatment in the placebo-controlled study we conducted in a large subset of patients included 5 
in the present analysis (2). 
Our study is the first that compared the prevalence of respiratory viruses in symptomatic 
adults to that in matched controls without respiratory symptoms. FLU, HPIV 1-4 and RSV 
were never, or rarely, detected in controls or at follow-up in symptomatic patients. This 
strongly implicates these agents as causative pathogens. Similarly, the significantly lower 10 
prevalence of HRV, HMPV, and HCoV in patients at follow-up and in controls suggests that 
asymptomatic carriage of these viruses is uncommon in adults, and indicates that these viruses 
should also be regarded as causative agents in CAP (11),14,(23). 
For HRV, the rates of prolonged shedding (same genotype in 35%) versus reinfection (other 
genotype) in the GRACE study have been further investigated (24).  15 
HBoV was detected in CAP and in <1% of LRTI patients a  baseline, with similar findings 
among controls and at of follow up of patients. HBoV was identified in respiratory specimens 
from 1.5% hospitalized adults with no alternate viral aetiology, but controls were not included 
in that study (25). Since HBoV is often found in the presence of other pathogens in 
respiratory specimens we agree that HBoV probably has no relevance or primary role as a 20 
causative agent in LRTI in primary care (26). There may be an association between high 
HBoV viral loads and HBoV being the only virus detected (27), suggesting a quantitative 
approach should be considered (26). 
This also applies to KIPyV and WUPyV. Although it is not yet possible to draw firm 















causative role in outpatient CAP or LRTI: assessment of the viral loads could potentially help 
to further clarify their significance as well. 
 
Limitations  
Sputum was not obtained from all patients, and sputa and follow-up serology was not 5 
obtained from control patients. Consequently, a valid estimation of the prevalence of bacterial 
pathogens in controls was not always possible. A though the most important elements of this 
study are the descriptive results, we also performed ultiple statistical tests so the finding of 
statistical significance may reflect type I error. However this is much less likely when 
supporting prior work on aetiology (e.g. bacterial c uses of CAP) or when the p-value is very 10 
small (e.g. the case-control comparisons of viral aetiology). 
 
Conclusions and implications for future management of LRTI 
This unique comprehensive prospective study using modern microbiological methods 
suggests that the traditional view of aetiology in CAP and outpatient LRTI should be revised. 15 
We have found that viral CAP and LRTI is also caused by HRV, HCoV and HMPV. Our high 
viral detection rates should also inform clinical decision making.  Better diagnostics are 
needed to distinguish viral from bacterial CAP or LRTI at the point of care.  
 
The current study provides microbiological evidence why antibiotics do not help patients with 20 
LRTI. Only approximately one in five LRTI patients have a bacterial pathogen isolated and so 
could conceivably benefit from antibiotic treatment. This evidence should support primary 
care clinicians’ restrictive approach to antibiotic prescribing for LRTI. If they consider 
antibiotics are indeed indicated, the low resistance levels in S. pneumoniae and H. influenzae 
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Table 1. Age and gender of all patients with LRTI, LRTI with CAP, LRTI without CAP, and 
of matched controls 
 










Gender     
Males, n= (%) 1244 (40.0) 62 (44.0) 1182 (39.9) 820 (39.7) 
Females, n= (%) 1860 (60.0) 79 (56.0) 1781 (60.1) 1243 (60.3) 
Age     
Mean (SD) 49.8 (16.8) 53.9 (15.3) 49.4 (16.6) 49.5 (16.6) 
Range 18-92 19-87 18-92 18-92 
Above 65years, n= (%)  628 (20.2) 40 (28.4) 588 (19.8) 385 (18.7) 
 
*  Data missing for three patients. 5 
** Matched for age (maximum five years of differenc) and gender, and consulting the same 















Table 2. Organisms detected in patients with LRTI, LRTI with CAP and LRTI without CAP 
 
Organisms LRTI  
( n=3104) 






Bacteria n (%) n (%) n (%)  
S. pneumoniae 172 (5.5) 13 (9.2)  159 (5.4) 0.043 
H. influenzae 167 (5.4) 20 (14.2) 147 (5.0) <0.001 
M. pneumoniae 150 (4.8) 6 (4.3) 144 (4.9) 0.738 
C. pneumoniae 165 (5.3) 7 (5.0) 158 (5.3) 0.843 
B. pertussis 95 (3.1) 4 (2.8) 91 (3.1)   1.000* 
L. pneumophila         6 (0.2)            1 (0.7)        5 (0.2)   0.236* 
Any of the above bacteria 655 (21.1) 42 (29.8) 613 (20.7) 0.010 
     
Viruses     
Rhinovirus 623 (20.1) 20 (14.2) 603 (20.4) 0.066 
Influenza A/B 307 (9.9) 11 (7.8) 296 (10.0) 0.378 
Coronavirus 231 (7.4) 6 (4.3) 225 (7.6) 0.134 
Respiratory syncytial 
virus 
144 (4.6) 4 (2.8) 140 (4.7) 0.289 
Human metapneumovirus 138 (4.4) 9 (6.4) 129 (4.4) 0.264 
Parainfluenzaviruses 1-4 81 (2.6) 4 (2.8) 77 (2.6)   0.786* 
Human adenovirus 41 (1.3) 5 (3.5) 36 (1.2)   0.037* 
Polyomaviruses 69 (2.2) 2 (1.4) 69 (2.3)   0.769* 
Bocavirus 18 (0.6) 0 (0.0) 18 (0.6)   1.000* 
Any of the above viruses 1494 (48.1) 53 (37.6)  1441 (48.7) 0.010 
 















Table 3. Viruses detected in LRTI patients and their matched controls 
 
*  Denominator varies per aetiological agent due to ‘not tested’ in max 0.6% on day 1 and 3.7% of 
samples on day 28-35 and missing data in controls. 
†  The Generalized Estimating Equations took clustering of Day 1 and Day 28-35 samples within the 5 
same patients and clustering of Day 1 samples of patients and their matched controls into account. 
 
 Patients with LRTI,  Matched controls 




P-value† (n=2063)* P-value† 
 
Rhinoviruses 623 (20.1)  113 (4.2) <0.0001  72 (3.5) <0.0001 
Influenza A/B 307 (9.9)   11 (0.4) <0.0001   7 (0.3) <0.0001 
Coronaviruses  231 (7.4)   71 (2.7) <0.0001  29 (1.4) <0.0001 
Respiratory syncytial virus  144 (4.6)   13 (0.5) <0.0001  10 (0.5) <0.0001 
Human metapneumovirus 138 (4.4)    7 (0.3) <0.0001   3 ( 0.1) <0.0001 
Parainfluenzaviruses 1-4  81 (2.6)   13 (0.5) <0.001   7 (0.3) <0.0001 
Adenoviruses  41 (1.3)   42 (1.6) 0.328  23 (1.1) 0.831 
Polyomavirus  69 (2.2)   82 (3.1) 0.017  52 (2.5) 0.060 
Polyomavirus WU 44 (1.4)   54 (2.0)   36 (1.7)  
Polyomavirus KI 27 (0.9)   28 (1.0)   17 (0.8)  















Table 4. Viruses and atypical bacteria detected at baseline (acute phase of illness) and at  
follow-up within the same patient 
 
Virus or atypical detection by PCR Baseline (acute illn ss)  
n (%) of total 
(n=3104) 
At follow-up 
n (%) of positives during 
the acute phase 
Bacteria   
M. pneumoniae 31 (1.0) 0 (0.0) 
C. pneumoniae 26 (0.8) 1 (3.8) 
B. pertussis 39 (1.3) 0 (0.0) 
   
Viruses   
Rhinovirus 623 (20.1) 27 (4.3) 
Influenza A/B 307 (9.9)  0 (0.0) 
Coronaviruses 231 (7.4) 4 (1.7) 
Respiratory syncytial virus 144 (4.6) 1 (0.7) 
Human metapneumovirus 138 (4.4) 1 (0.7) 
Parainfluenzaviruses 1-4 81 (2.6) 0 (0.0) 
Adenoviruses 41 (1.3) 2 (4.9) 
Polyomaviruses (WU+KI) 69 (2.2) 2 (2.9) 

















Figure 1. Venn diagrams of percentages (numbers) of patients with no, a bacterial, a viral or a 
mixed bacterial and viral aetiology detected in (a) 3104 patient with lower respiratory tract 
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